English
Anti-DLL3-Anti-CD3 Bispecific Molecule
Anti-DLL3-Anti-CD3 Bispecific Molecule
Artikelnummer
BPS102209-2
Verpackungseinheit
100 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Application: The Anti-DLL3-Anti-CD3 Bispecific Molecule can be used for studying DLL3+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621).
Assay Conditions: NFAT Luciferase Reporter Jurkat cells (BPS Bioscience #60621) were incubated with increasing concentrations of Anti DLL3-Anti-CD3 Bispecific Molecule in the presence of DLL3 CHO cells (BPS Bioscience #78882) or CHO cells (ATCC #CCL-61™). Luciferase activity was measured using ONE-Step™ Luciferase Assay System (BPS Bioscience #60690).
Background: DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine).
Description: Anti-DLL3-Anti-CD3 Bispecific Molecule is a purified recombinant human bispecific molecule with T cell Engager. This bispecific molecule has been tested for specific activity in a functional reporter assay using NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) co-cultured with DLL3 CHO Cell Line (BPS Bioscience #78882).
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Uniprot: DLL3: Q9NYJ7
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
Application: The Anti-DLL3-Anti-CD3 Bispecific Molecule can be used for studying DLL3+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621).
Assay Conditions: NFAT Luciferase Reporter Jurkat cells (BPS Bioscience #60621) were incubated with increasing concentrations of Anti DLL3-Anti-CD3 Bispecific Molecule in the presence of DLL3 CHO cells (BPS Bioscience #78882) or CHO cells (ATCC #CCL-61™). Luciferase activity was measured using ONE-Step™ Luciferase Assay System (BPS Bioscience #60690).
Background: DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine).
Description: Anti-DLL3-Anti-CD3 Bispecific Molecule is a purified recombinant human bispecific molecule with T cell Engager. This bispecific molecule has been tested for specific activity in a functional reporter assay using NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) co-cultured with DLL3 CHO Cell Line (BPS Bioscience #78882).
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Uniprot: DLL3: Q9NYJ7
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
| Artikelnummer | BPS102209-2 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 102209-2 |
| Verpackungseinheit | 100 µg |
| Mengeneinheit | STK |
| Klonalität | Monoclonal |
| Isotyp | IgG1 |
| Wirt | Human |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
